WO1997008309A9 - Ribozyme therapy for hepatitis b infections - Google Patents
Ribozyme therapy for hepatitis b infectionsInfo
- Publication number
- WO1997008309A9 WO1997008309A9 PCT/US1996/013975 US9613975W WO9708309A9 WO 1997008309 A9 WO1997008309 A9 WO 1997008309A9 US 9613975 W US9613975 W US 9613975W WO 9708309 A9 WO9708309 A9 WO 9708309A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ribozyme
- cell
- hbv
- dna
- promoter
- Prior art date
Links
- 229920002033 ribozyme Polymers 0.000 title claims abstract description 149
- 208000002672 Hepatitis B Diseases 0.000 title claims description 11
- 238000002560 therapeutic procedure Methods 0.000 title description 8
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims abstract description 54
- 201000009910 diseases by infectious agent Diseases 0.000 claims abstract description 22
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 36
- 229920001364 Hairpin ribozyme Polymers 0.000 claims description 19
- 108090001052 hairpin ribozyme Proteins 0.000 claims description 13
- 230000001177 retroviral Effects 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 206010047461 Viral infection Diseases 0.000 claims description 7
- 208000001756 Virus Disease Diseases 0.000 claims description 7
- 241001430294 unidentified retrovirus Species 0.000 claims description 7
- 230000029812 viral genome replication Effects 0.000 claims description 7
- 230000017613 viral reproduction Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000002452 interceptive Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 229920002676 Complementary DNA Polymers 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 229920000970 Repeated sequence (DNA) Polymers 0.000 claims description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 abstract description 56
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 210000004027 cells Anatomy 0.000 description 75
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 32
- 239000000758 substrate Substances 0.000 description 30
- 238000003776 cleavage reaction Methods 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 26
- 125000003729 nucleotide group Chemical group 0.000 description 24
- 230000000694 effects Effects 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 210000004185 Liver Anatomy 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 8
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000002194 synthesizing Effects 0.000 description 7
- 230000003612 virological Effects 0.000 description 7
- 229920001850 Nucleic acid sequence Polymers 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 229920001941 Hammerhead ribozyme Polymers 0.000 description 5
- 102100011960 MIR7-3HG Human genes 0.000 description 5
- 101710008473 MIR7-3HG Proteins 0.000 description 5
- 229920000272 Oligonucleotide Polymers 0.000 description 5
- 102000006382 Ribonucleases Human genes 0.000 description 5
- 108010083644 Ribonucleases Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000000295 complement Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N Spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- 108010003152 bacteriophage T7 RNA polymerase Proteins 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 230000003197 catalytic Effects 0.000 description 4
- 230000001684 chronic Effects 0.000 description 4
- 108090001102 hammerhead ribozyme Proteins 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000692 anti-sense Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000001965 increased Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 108091007521 restriction endonucleases Proteins 0.000 description 3
- 102100001249 ALB Human genes 0.000 description 2
- 101700011961 DPOM Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 101700036757 ERN1 Proteins 0.000 description 2
- 102100016655 ERN1 Human genes 0.000 description 2
- 101700014948 ERN2 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000005331 Hepatitis D Diseases 0.000 description 2
- 101700085586 IRE1A Proteins 0.000 description 2
- 101700019719 IRE1B Proteins 0.000 description 2
- 101710029649 MDV043 Proteins 0.000 description 2
- 210000000282 Nails Anatomy 0.000 description 2
- 101700061424 POLB Proteins 0.000 description 2
- DTBNBXWJWCWCIK-UHFFFAOYSA-N Phosphoenolpyruvic acid Natural products OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 2
- 101700054624 RF1 Proteins 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M Sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 229920001949 Transfer RNA Polymers 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000038129 antigens Human genes 0.000 description 2
- 108091007172 antigens Proteins 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002255 enzymatic Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002440 hepatic Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 101700052395 ire-1 Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- -1 phosphothio Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940063673 spermidine Drugs 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
- 102100008450 AFP Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 102100001085 APOB Human genes 0.000 description 1
- 101700065507 APOB Proteins 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 210000002421 Cell Wall Anatomy 0.000 description 1
- 229920000453 Consensus sequence Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241001533413 Deltavirus Species 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-N Deoxycytidine triphosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N Deoxyguanosine triphosphate Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 235000004418 Durio kutejensis Nutrition 0.000 description 1
- 102000007698 EC 1.1.1.1 Human genes 0.000 description 1
- 108010021809 EC 1.1.1.1 Proteins 0.000 description 1
- 108010021582 EC 2.7.1.2 Proteins 0.000 description 1
- 102000019622 EC 2.7.1.2 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100009906 F7 Human genes 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 229940012952 Fibrinogen Drugs 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920001809 Group I catalytic intron Polymers 0.000 description 1
- NYHBQMYGNKIUIF-PXMDKTAGSA-N Guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1O[C@@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-PXMDKTAGSA-N 0.000 description 1
- 229940029575 Guanosine Drugs 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 210000002767 Hepatic Artery Anatomy 0.000 description 1
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 1
- 208000006454 Hepatitis Diseases 0.000 description 1
- 208000005252 Hepatitis A Diseases 0.000 description 1
- 229920000900 Hepatitis delta virus ribozyme Polymers 0.000 description 1
- 206010019780 Hepatitis infectious Diseases 0.000 description 1
- 210000003494 Hepatocytes Anatomy 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102100005410 LINE-1 retrotransposable element ORF2 protein Human genes 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 230000036223 MICHAELIS CONSTANT Effects 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101700030082 PCK2 Proteins 0.000 description 1
- 102100019741 PCK2 Human genes 0.000 description 1
- 101710042135 PPi-PFK Proteins 0.000 description 1
- 108091005771 Peptidases Proteins 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 210000003240 Portal Vein Anatomy 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 102000020497 RNA-Binding Proteins Human genes 0.000 description 1
- 108091022184 RNA-Binding Proteins Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 108020004418 Ribosomal RNA Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229940054269 Sodium Pyruvate Drugs 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000223892 Tetrahymena Species 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- PGAVKCOVUIYSFO-XVFCMESISA-N Uridine triphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 PGAVKCOVUIYSFO-XVFCMESISA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 210000002845 Virion Anatomy 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 101710039743 acu-6 Proteins 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 229920002092 cellular RNA Polymers 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-J dATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-J 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012413 factor VII Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003494 hepatotrophic Effects 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101700033304 pckG Proteins 0.000 description 1
- 101710036149 pfk-1.2 Proteins 0.000 description 1
- 101700087004 pfkA1 Proteins 0.000 description 1
- 101700035696 pfkB Proteins 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 108010045647 puromycin N-acetyltransferase Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229920002973 ribosomal RNA Polymers 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical class [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000002463 transducing Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 229950010342 uridine triphosphate Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Definitions
- the present invention relates generally to therapeutics, and more specifically, to compositions and methods which utilize ribozymes in the treatment of Hepatitis B infections
- HBV infection remains a worldwide health problem, with estimates of over 300 million chronically infected individuals The Center for Disease Control (“CDC”) estimates that there are approximately 1 million carriers in the United States and over 300,000 new infections per year Chronic HBV infection is a major cause of liver cirrhosis. HBV infection also is associated with one of the most common visceral malignancies worldwide, primary hepatocellular carcinoma In areas of the world where HBV infection is endemic, hepatocellular carcinoma (“HCC”) is among the most common lethal malignancies.
- HCC hepatocellular carcinoma
- the present invention provides ribozymes useful to treat or prevent Hepatitis B Virus ("HBV”) infection in an organism or subject, as well as methods of treating an HBV infection.
- Reagents such as vectors, host cells, DNA molecules coding for these ribozymes useful in methods of treatment and prevention of HBV infection also are provided.
- the present invention provides ribozymes having the ability to inhibit replication and infectivity of a hepatitis B virus.
- the ribozyme is a hammerhead or hairpin ribozyme, representative examples of which recognize the sequences set forth in Table I , below.
- the present invention also provides a nucleic acid molecule encoding such ribozymes; further preferably, the nucleic acid is DNA or cDNA Even further preferably, the nucleic acid molecule is under the control of a promoter to transcribe the nucleic acid.
- the present invention provides host cells containing the ribozymes described herein, vectors comprising the nucleic acid encoding the ribozymes desc ⁇ bed herein, and host cells comprising such a vector.
- the vector is a plasmid, a virus, retrotransposon, a cosmid or a retrovirus.
- the nucleic acid molecule encoding the ribozyme under the control of a promoter which is preferably a pol III promoter, further preferably a human tRNA Vnl promoter or an adenovirus VA1 promoter, is inserted between the 5' and 3' long terminal repeat sequences of the retrovirus.
- the present invention also provides a host cell stably transformed with such a retroviral vector.
- the host cell is a murine or a human cell.
- the present invention provides methods for producing a ribozyme, the ribozyme being able to inhibit hepatitis B viral infection and replication in a cell, which method comprises providing a nucleic acid molecule (e.g., DNA) encoding the ribozyme under the transcriptional control of a promoter, and transcribing the nucleic acid molecule to produce the ribozyme.
- the method further comprises purifying the ribozyme produced.
- the ribozyme may be produced / ' /; vitro, in vivo or ex vivo.
- the present invention provides methods of interfering with or preventing HBV replication in a cell infected with HBV, which method comprises introducing into the cell an effective amount of the ribozymes described herein.
- such methods comprise introducing into the cell an effective amount of DNA encoding a ribozyme as described herein and transcribing the DNA to produce the ribozyme.
- the cell is a human cell.
- the present invention provides methods of preventing hepatitis B viral infection in a cell susceptible to infection with HBV, which methods comprise introducing into the cell an effective amount of a nucleic acid molecule (e.g., DNA) encoding a ribozyme as described herein and transcribing the
- the cell is a human cell.
- the methods further comprise administering the cell transduced with a retroviral vector to a mammal of the same species as that from which the transduced cell was obtained.
- the cell transduced with the retroviral vector has been obtained from the mammal receiving the transduced cell.
- Figure 1 is a schematic illustration of vector pLNT-Rz
- Figures 2A, 2B, 2C and 2D are schematic representations of HBV and ribozyme expression vectors, and wild type and tetraloop hairpin ribozyme structures.
- Figure 2A discloses "overlength" HBV as cloned into pGem7 The pre-genomic RNA (pgRNA) start site and common polyA signal are indicated.
- pgRNA pre-genomic RNA
- RNA transcripts are driven by authentic HBV promoters
- Cleavage sites for hairpin ribozymes BR1, BR2 and BR3 are indicated by downward arrows HBV-encoded proteins X, C (core), S (envelope) and P (polymerase) are shown as boxes below
- Figure 2B discloses a ribozyme in the retroviral vector pLNT-Rz, which is used for ribozyme expression in mammalian cells
- ribozymes are cloned under the control of the human tRNA val promoter ("LTR" Moloney Long Terminal Repeat)
- the hairpin ribozyme consists of a 50 to 54 nucleotide RNA molecule (shaded, in uppercase letters) which binds and cleaves an RNA substrate (lowercase letters).
- the length of Helix 2 is fixed at 4 basepairs and the length of Helix I typically varies from 6 to 10 basepairs, with 8 being experimentally optimal for most ribozymes.
- the substrate must contain a GUC in Loop 5 for maximal activity, and cleavage occurs immediately 5' of the G as indicated by an arrow.
- the catalytic, but not substrate binding, activity of the ribozyme can be disabled by mutating the AAA in Loop 2 to CGU, as shown.
- the tetraloop hairpin ribozyme ( Figure 2D) differs from the hairpin ribozyme by replacement of Loop 3 and Helix 4 with the RNA-stabilizing tetraloop configuration.
- Figure 3 depicts the results of n vitro cleavage experiments of HBV RNA by BR1 and BR3 ribozymes Ribozymes BR1 and BR3, as well as their disabled counterparts, dBR l and dBR3 were tested Briefly, ribozymes and radiolabeled HBV substrate were synthesized by /// vitro transcription.
- Figures 4A and 4B depicts the results of n vitro kinetic studies for BRl and tetraloop BRl ( Figure 4 A), and BR3 and tetraloop BR3 ( Figure 4B) Shown are typical in vitro cleavage reaction timecourse experiments, including 5 2 nM ribozyme and 72 nM substrate The reactions were incubated at 37°C and aliquots were removed every 30 minutes fiom 0 to 120 minutes, as indicated Cleavage products were quantitated by phosphorimager analyses
- Figures 5A and 5B show ribozyme expression /// vitro verified by RNase protection
- Huh7 cells were transfected with each of the ribozymes indicated Twenty-five micrograms of total cellular RNA was hybridized to 128 nucleotide radiolabeled probes, of equal, specific activity, antisense to either BRl or BR3, as indicated Following RNase digestion, reactions were electrophoresed on a 8% polyacrylamide/7M urea gel and quantitated by phosphorimager analysis.
- the expected protected fragments are 64 nt for BR l and BR3, and 32 nt + 29 nt for dBR l and dBR3 (see panel 5B for schematic representation of protected fragments)
- FIGS 6A and 6B show that expression of anti-HBV ribozymes reduces Hepatitis B virus production in liver cell culture
- Huh7 cells were co- transfected with overlength HBV and pLNT-Rz for each ribozyme
- the DNA molar ratio for HBV ribozyme ranged from I 5 to 1 20, as indicated
- Figure 6A shows a typical endogenous polymerase assay with radiolabeled HBV DNA resolved by agarose gel electrophoresis, with relaxed circular (R C ) and linear forms indicated
- Figure 6B shows quantitation as performed by phosphorimager analysis Values are pixel volumes generated following phosphorimager scanning. Percentages listed above graph bars indicate percent reduction of HBV production by each ribozyme, relative to HBV transfections without ribozyme (first bar on graph).
- Ribozyme refers to a nucleic acid molecule which is capable of cleaving a specific nucleic acid sequence. Ribozymes may be composed of RNA, DNA, nucleic acid analogues (e.g., phosphorothioates), or any combination of these (e.g., DNA/RNA chimerics). Within particularly preferred embodiments, a ribozyme should be understood to refer to RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity
- Ribozyme gene refers to a nucleic acid molecule (e.g., DNA) consisting of the ribozyme sequence which, when transcribed into RNA, will yield the ribozyme.
- Vector refers to an assembly which is capable of expressing a ribozyme of interest.
- the vector may be composed of either deoxyribonucleic acids ("DNA”) or ribonucleic acids ("RNA").
- the vector may include a polyadenylation sequence, one or more restriction sites, as well as one or more selectable markers such as neomycin phosphotransferase, hygromycin phosphotransferase or puromycin-N-acetyl-transferase.
- the present invention provides ribozymes which are capable of cleaving Hepatitis B viral nucleic acids.
- the viral genome of HBV is about 3000 to 3300 nucleotides in length.
- the viral DNA is circular, both strands of the viral duplex are linear, and the circular conformation is maintained by extensive base-pairing between the two gapped DNA strands.
- the negative strand of the virus is about 3200 nucleotides in length while the positive strand is shorter, due to single-stranded gaps of variable size.
- the HBV DNA polymerase in the nucleocapsid core is activated and completes the synthesis of the positive strand, using the negative strand as a template.
- RNA is transcribed from the DNA template. It is believed that this pregenome RNA is packaged within the cell to form an "immature core," and by reverse transcription, a DNA strand of negative polarity is synthesized. This step is followed by the synthesis of a partial positive strand and the full maturation of the virus particle containing a gapped DNA genome.
- the pregenome RNA and the mRNA of the virus which is the target of the ribozymes of this invention.
- Successful inhibition at this stage in the viral cycle can potentially eliminate hepatic and extrahepatic replication and transmission in all infected patients, including chronic carriers.
- An additional benefit is the prevention of Hepatitis D viral infection which require HBsAg as its envelope.
- the present invention provides ribozymes having the ability to inhibit replication, infectivity, or gene expression of a hepatitis B viral infection in a cell.
- ribozymes having the ability to inhibit replication, infectivity, or gene expression of a hepatitis B viral infection in a cell.
- ribozymes may be constructed for use within the present invention, including for example, hammerhead ribozymes (Rossi, J.J. et al., Pharmac. Ther.
- Cech et al. (U.S. Patent No. 4,987,071 , issued January 22, 1991) has disclosed the preparation and use of certain synthetic ribozymes which have endoribonuclease activity These ribozymes are based on the properties of the Tetrahymena ribosomal RNA self-splicing reaction and require an eight base pair target site with a requirement for free guanosine or guanosine derivatives A temperature optimum of 50°C is reported for the endoribonuclease activity The fragments that arise from cleavage contain 5'-phosphate and 3'-hydroxyl groups and a free guanosine nucleotide added to the 5'-end of the cleaved RNA In contrast, the ribozymes of this invention hybridize efficiently to target sequences at physiological temperatures, making them suitable for use in vivo, not merely as research tools (see column 15, lines 18 to 42, of Cech et al , U.S Patent No 4,987,07
- ribozymes for use within the present invention are hairpin ribozymes (for example, as described by Hampel et al., European Patent Publication No 0 360 257, published March 26, 1990)
- the sequence requirement for the hairpin ribozyme is any RNA sequence consisting of NNNBN*GUC(N) (Sequence ID Nos. 1-5) (where x is any number from 6 to 10, N*G is the cleavage site, B is any of G, C, or U, and N is any of G, U, C, or A).
- Representative examples of recognition or target sequences for hairpin ribozymes are set forth below in the Examples.
- the backbone or common region of the hai ⁇ in ribozyme can be designed using the nucleotide sequence of the native hairpin ribozyme (Hampel et al., Nncl. Acid.s Res. 18 299-304, 1990) or it can be modified to include a "tetraloop" structure that increases stability and catalytic activity (see Example 2 and Figure 3; see also Yu et al , Virology 2f :38 I -386, 1995, Cheong et al., Nature 3- 6:680-682, 1990, Anderson et al , Nitcl. Acids Res. 22: 1096-1 100, 1994).
- the sequence requirement at the cleavage site for the hammerhead ribozyme is any RNA sequence consisting of NUX (where N is any of G, U, C, or A and X represents C, U, or A) can be targeted. Accordingly, the same target within the hairpin leader sequence, GUC, is useful for the hammerhead ribozyme
- the additional nucleotides of the hammerhead ribozyme or hairpin ribozyme is determined by the target flanking nucleotides and the hammerhead consensus sequence (see Ruffner et al.. Biochemistry 29: 10695- 10702, 1990).
- ribozymes of the present invention may be readily constructed Appropriate base changes in the ribozyme are made to maintain the necessary base pairing with the target HBV sequences.
- GenBank i.e., accession numbers V00866, J02201, X00715, for HBV ADW
- other sources i.e., GenBank (i.e., accession numbers V00866, J02201, X00715, for HBV ADW), as well as other sources.
- ribozymes of this invention can be chemically synthesized using methods well known in the art for the synthesis of nucleic acid molecules (see e.g., Heidenreich et al., J. FASEB 70( l ):90-6, 1993; Sproat, Curr. Opin. Biotechnol. - ( l ):20-28, 1993), .
- Promega, Madison, Wis., USA provides a series of protocols suitable for the production of nucleic acid molecules such as ribozymes.
- ribozymes can also be prepared from a DNA molecule or other nucleic acid molecule (which, upon transcription, yields an RNA molecule) operably linked to an RNA polymerase promoter, e.g., the promoter for T7 RNA polymerase or SP6 RNA polymerase.
- an RNA polymerase promoter e.g., the promoter for T7 RNA polymerase or SP6 RNA polymerase.
- nucleic acid molecules e.g., DNA or cDNA, coding for the ribozymes of this invention
- the vector also contains an RNA polymerase promoter operably linked to the DNA molecule, the ribozyme can be produced ; ' /; vitro upon incubation with the RNA polymerase and appropriate nucleotides.
- the DNA may be inserted into an expression cassette, such as described in Cotten and Birnstiel, EMBO .1. ⁇ '( 12):3861 -3866, 1989, and in Hempel et al.. Biochemistry 2 ⁇ S':4929-4933, 1989.
- an expression cassette such as described in Cotten and Birnstiel, EMBO .1. ⁇ '( 12):3861 -3866, 1989, and in Hempel et al.. Biochemistry 2 ⁇ S':4929-4933, 1989.
- a more detailed discussion of molecular biology methodology is disclosed in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, 1989
- the ribozyme can be modified by ligation to a DNA molecule having the ability to stabilize the ribozyme and make it resistant to RNase (Rossi et al., Pharn ac. Ther. 50.245-254, 1991 )
- the ribozyme can be modified to the phosphothio analog for use in liposome delivery systems This modification also renders the ribozyme resistant to endonuclease activity
- V ⁇ CTORS Use of ribozymes to treat HBV infection involves introduction of functional ribozyme to the infected cell of interest This can be accomplished by either synthesizing functional ribozyme in vitro prior to delivery, or, by delivery of DNA capable of driving ribozyme synthesis /// vivo
- the ribozyme gene may be constructed within a vector which is suitable for introduction to a host cell (e.g., prokaryotic or eukaryotic cells in culture or in the cells of an organism).
- a host cell e.g., prokaryotic or eukaryotic cells in culture or in the cells of an organism.
- Appropriate prokaryotic and eukaryotic cells can be transfected with an appropriate transfer vector containing the nucleic acid molecule encoding a ribozyme of this invention.
- nucleotide sequences coding for ribozymes are preferably placed under the control of a eukaryotic promoter such as pol III (e.g., tRNA or VA- 1 from adenovirus), CMV, SV40 late, or SV40 early promoters.
- a eukaryotic promoter such as pol III (e.g., tRNA or VA- 1 from adenovirus), CMV, SV40 late, or SV40 early promoters.
- the promoter may be a tissue-specific promoter such as, for example, a liver-specific promoter such as the albumin promoter and the alphafetoprotein promoter (Feuerman et al , Mol. Cell. Biol. 9 4204-12, 1989; Camper and Tilghman, denes Develop.
- the alcohol dehydrogenase promoter (Felder, Proc. Natl. Acad. Sci. USA 86 5903-07, 1989), the Apolipoprotein B gene promoter (Das et al , J. Biol. Chem 263 1 1452-8, 1988), the Coagulation protease factor VII gene promoter (Erdmann et al , J. Biol. Chem. 270.22988-96, 1995); the Fibrinogen gamma gene promoter (Zhang et al , J. Biol. Chem. 270.24287- 91, 1995); the Glucokinase gene promoter (Williams et al , Biochem. Biophys., Res.
- the Liver phosphofructokinase gene promoter (Levanon et al., Biochem. Mol. Biol. Int 35 729-36, 1995), the Phospho-Enol-Pyruvate Carboxy- Kinase ("PEPCK”) promoter (Hatzogiou et al , J. Biol. Chem. 263: 17798-808, 1988, Benvenisty et al., Proc. Nail. Acad. Sci. USA 86 1 1 18-22, 1989, Vaulont et al., Mol. Cell. Biol. 9 4409- 15, 1989), or lymphoid-specific promoters Ribozymes may thus be produced directly from the transfer vector /// vivo
- vectors may be utilized within the context of the present invention, including for example, plasmids, viruses, retrotransposons and cosmids Because HBV infects the liver, vectors with hepatotrophic properties are particularly preferred Representative examples include adenoviral vectors (e.g. , WO 94/26914, WO 93/9191 , Yei et al , dene Therapy I 192-200, 1994, Kolls et al , PNAS 97(1 ) 215-219, 1 94, Kass-Eisler et al , PNAS 90(24) 1 1498-502, 1 93, Guzman et al .
- adenoviral vectors e.g. , WO 94/26914, WO 93/9191 , Yei et al , dene Therapy I 192-200, 1994, Kolls et al , PNAS 97(1 ) 215-219, 1 94, Kass-Eisler e
- Circulation 88(6) 2838-48 1993, Guzman et al , Cn: Res. 73(6) 1202- 1207, 1993, Zabner et al , Cell 75(2).207-216, 1993, Li et al , Hum Gene Ther. 4(4) 403- 409, 1993, Caillaud et al , / • ;///-. J Neitrosci.
- vectors having more than one nucleic acid molecule encoding a ribozyme of this invention, each molecule under the control of a separate eukaryotic promoter or alternatively, under the control of single eukaryotic promoter.
- therapeutic molecules which may be delivered by the vectors ofthe present invention include interferon (e.g., alpha, beta or gamma), as well as a wide variety of other cytokines or growth factors.
- Host prokaryotic and eukaryotic cells stably harboring the vectors described above also are provided by this invention Suitable host cells include bacterial cells, rat cells, mouse cells, and human cells, for example, liver and blood cells.
- ribozyme molecules may be introduced into a host cell utilizing a vehicle, or by various physical methods Representative examples of such methods include transformation using calcium phosphate precipitation (Dubensky et al., PNAS 57:7529-7533, 1984), direct microinjection of such nucleic acid molecules into intact target cells (Acsadi et al.. Nature 352:81 -818, 1991 ), and electroporation whereby cells suspended in a conducting solution are subjected to an intense electric field in order to transiently polarize the membrane, allowing entry of the nucleic acid molecules.
- nucleic acid molecules linked to an inactive adenovirus include the use of nucleic acid molecules linked to an inactive adenovirus (Cotton et al., PNAS ⁇ '9:6094, 1990), lipofection (Feigner et al., Proc. Nail. Acad. Sci. USA 84.7413-7417, 1989), microprojectile bombardment (Williams et al., PNAS ⁇ 7?:2726-2730, 1991 ), polycation compounds such as polylysine, receptor specific ligands, liposomes entrapping the nucleic acid molecules, spheroplast fusion whereby E.
- coli containing the nucleic acid molecules are stripped of their outer cell walls and fused to animal cells using polyethylene glycol, viral transduction, (Cline et al., Pharmac. Ther. 29:69, 1985; and Friedmann et al.. Science 244: 1275, 1989), and DNA ligand (Wu et al, J. of Biol. Chem. 2r : 16985- 16987, 1989).
- the ribozyme is introduced into the host cell using a liposome.
- PH ⁇ RM ⁇ CF.I ⁇ TIC ⁇ I . >MI* ⁇ >SITK >NS pharmaceutical compositions also are provided by this invention.
- compositions contain any of the above described ribozymes, DNA molecules, vectors or host cells, along with a pharmaceutically or physiologically acceptable carrier, excipients or diluents.
- a pharmaceutically or physiologically acceptable carrier should be nontoxic to recipients at the dosages and concentrations employed.
- the preparation of such compositions entails combining the therapeutic agent with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients.
- compositions of the present invention may be prepared for administration by a variety of different routes, including for example intraarticularly, intracranially, intradermally, intrahepatically, intramuscularly, intraocularly, intraperitoneally, intrathecally, intravenously (e.g., into the portal vein), or subcutaneously.
- pharmaceutical compositions of the present invention may be placed within containers, along with packaging material which provides instructions regarding the use of such pharmaceutical compositions.
- such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient ingredients or diluents (e.g., water, saline or PBS) which may be necessary to reconstitute the pharmaceutical composition
- RNA molecules can be embedded within a stable RNA molecule or in another form of protective environment, such as a liposome.
- the RNA can be embedded within RNase-resistant DNA counterparts.
- Cellular uptake of the exogenous ribozyme can be enhanced by attaching chemical groups to the DNA ends, such as cholesteryl moieties (Letsinger et al , /'.N. ⁇ . ⁇ '., U.S.A., 1989)
- he target cell is transduced under conditions favoring insertion of the vector into the target cell and stable expression of the nucleic acid encoding the HBV specific ribozyme.
- the target cell can include but is not limited to hepatocytes and lymphocytes If the cell is transduced prior to HBV infection, infection of the target cell or its progeny can be prevented. Accordingly, this aspect includes methods for interfering with or preventing HBV viral infection and/or replication in a cell by reacting the target RNA sequence with a ribozyme of this invention
- appropriate host cells such as liver cells are removed from a subject, e.g., a human patient, using methods well known in the art. The cells are then trypsinized and resuspended for ex vivo therapy.
- a transfer vector as described above encoding one or more ribozymes is transfected into a cell or cells using methods described in Llewellyn et a!., . Mol. Biol. 195: 1 15-123, 1987, and Hanahan, 7o7>:557-580, 1983.
- the transfer vector replicates and the DNA coding for the ribozyme is transcribed by cellular polymerases to produce ribozymes which then inactivate HBV
- Mici manipulation techniques such as microinjection also can be used to insert the vector into the cell so that the transfer vector or a part thereof is integrated into the genome of the ceil Transcription of the integrated material gives rise to ribozymes which then inactivate HBV.
- the above methods are not intended to limit the invention, but merely to exemplify various means to effect the ribozyme therapy of this invention Other methods are detailed in Anderson, Science 256:808-813, 1992.
- the transduced cells can be reintroduced into the patient by hepatic artery injection under conditions such that the transduced cells will integrate into the liver.
- the term "interfering with or preventing" HBV viral replication in a cell means to reduce HBV replication or production of HBV components necessary for progeny virus in a cell as compared to a cell not being transiently or stably transduced with the ribozyme or a vector encoding the ribozyme.
- Simple and convenient assays to determine if HBV viral replication has been reduced include an ELISA assay for the presence, absence, or reduced presence of anti-HBV antibodies or hepatitis B antigens in the blood of the subject, RT-PCR or liver function tests. Such methods are well known to those of ordinary skill in the art.
- total RNA from transduced and infected "control" cells can be isolated and subjected to analysis by dot blot or northern blot and probed with HBV specific DNA to determine if HBV replication is reduced.
- reduction of HBV protein expression can also be used as an indicator of inhibition of HBV replication. A greater than fifty percent reduction in HBV replication as compared to control cells typically quantitates a prevention of HBV replication.
- Hairpin ribozymes suitable for use within the present invention preferably recognize the following sequence of HBV RNA.
- NNNBN*GUC(N) X Sequence ID No. 1 (where x is any number from 6 to 10, N*G is the cleavage site, B is any of G, C, or U, and N is any of G, U, C, or A)
- the sequence GUC must be conserved for all hairpin ribozymes described below
- Other nucleotides (“N” as provided above) preferably have a high degree of sequence conservation in order to limit the need for multiple ribozymes against the same target site GUC hairpin ribozyme recognition sites for HBV are provided below in Table 1.
- Two single-stranded DNA oligonucleotides are chemically synthesized such that, when combined and converted into double-stranded DNA, they contain the entire hairpin ribozyme, including nucleotides complementary to the target site.
- restriction enzyme recognition sites may be placed on either end to facilitate subsequent cloning. For example, in order to construct ribozyme BR3:
- the indicated oligonucleotides are hybridized together and converted to double-stranded DNA using either Klenow DNA polymerase or Taq DNA polymerase.
- the resulting DNA is cleaved with restriction enzymes BamHI and M ⁇ , purified and cloned into vectors for /// vitro transcription (pGEM, ProMega, Madison, Wis.) or for retrovirus production and mammalian expression (pLNL/MJT backbone).
- Defective or "disabled” ribozymes for use as controls may be constructed as described above, with the exception that the sequence AAA is changed to a UGC as shown in Figure 2.
- Ribozymes are cloned into in vitro transcription vectors (pGEM-7Z, ProMega, Madison, Wis.) and transcribed // vitro by T7 RNA polymerase. Following transcription, reactions are treated with RQ 1 DNase (Promega, Madison, Wisconsin) according to the manufacturer's instructions, and the ribozymes are purified by denaturing polyacrylamide gel electrophoresis.
- the /// vitro cleavage reactions contained 40 nM ribozyme and 200 nM substrate in 12 mM MgCl 2 /2 mM spermidine/40 mM Tris-HCl, pH 7.5, were incubated at 37°C for 60 minutes and were terminated by the addition of 7M urea gel loading buffer. Products of the cleavage reactions were resolved by electrophoresis on 5% polyacrylamide/7 M urea gels and analyzed by autoradiography. Results are shown in Figure 3. Briefly, ribozymes BRl and BR3 cleaved up to 35% of their substrate RNAs in 60 minutes, under physiological concentrations of magnesium, without any prior treatment or denaturation.
- dBRl and dBR3 As controls, the disabled forms of BRl and BR3 (designated dBRl and dBR3) were also tested.
- disabled ribozymes are made by introducing a three nucleotide mutation in loop 2 of the hairpin ribozyme. This inactivates its RNA cleavage activity, without affecting its substrate binding.
- dBRl nor dBR3 showed any RNA cleavage activity (lanes 4 and 8), indicating that the cleavage demonstrated by BRl and BR3 is specific Ribozyme BR2, however, showed no in vitro cleavage activity after 60 minutes (data not shown). Since both the BR2 ribozyme and its substrate target site were verified by DNA sequencing, the lack of cleavage activity was presumably due to RNA secondary structure within the substrate.
- Ribozyme and substrate synthesis was achieved by plasmid independent /// vitro transcription. Briefly, oligonucleotides were synthesized (Retrogen, San Diego) that contained the T7 RNA polymerase promoter and the ribozyme or substrate sequences.
- the universal T7 promoter oligo contains 63 nucleotides of random sequence ("template arm") and 17 nucleotides that make up the T7 promoter.
- the ribozyme oligo contains the 17 nucleotides complementary to the T7 promoter followed by a CCC (for optimal transcription) and the 50 bases encoding the ribozyme.
- the substrate oligos contain the T7 promoter, a CCC and the 33 or 34 nucleotides encoding the substrate.
- the two oligonucleotides were annealed and converted to double-stranded DNA using Klenow polymerase.
- n vitro transcription was carried using 4 ⁇ g of dsDNA template at 37°C for 2 hours using T7 RNA polymerase (Promega), according to the manufacturer's instructions.
- RNAs were labeled by incorporation of alpha P-CTP during the transcription reaction and purified by denaturing gel electrophoresis.
- Plasmid pMJT (Yu et al., Proc. Nat 'I Acad. Sci. USA 90:6340-6344, 1993), which contains the anti-U5 HIV ribozyme driven by the tRNA * "' RNA pol III promoter, is digested with BamHI and Mlu ⁇ , and the vector purified from the ribozyme fragment.
- the resulting plasmid, pGEM-HBV-overlength contains the entire pgRNA and polyA signal, as well as the authentic HBV pgRNA promoter When transfected into human liver cells, this plasmid will express HBV RNA and proteins, resulting in the secretion of infectious hepatitis B viral particles,
- Huh7 cells were cultured at 37°C in DMEM (Gibco BRL) supplemented with 10% FBS, L-glutamine, sodium pyruvate and antibiotics.
- DMEM Gibco BRL
- FBS FBS
- L-glutamine L-glutamine
- sodium pyruvate antibiotics.
- 1 x I O 6 cells on 100 mm plates were transfected with 1 ⁇ g pGEM- HBV-overlength plus 5 to 20 ⁇ g pLNT-Rz by standard calcium phosphate transfection procedures, using empty pLNT vector (containing no Rz sequences) to bring the total DNA to 20 ⁇ g.
- ribozyme expression was verified by RNase protection, according to the manufacturer (Promega). Results of this experiment are shown in Figures 5 A and 5B.
- HBV virus particles produced in tissue culture is best achieved using the endogenous polymerase assay (EPA) This assay relies on the fact that the packaged HBV genome is only partially double-stranded and that the HBV- specific polymerase is also packaged in each virion Addition of radiolabeled nucleotide triphosphates to purified HBV particles allows the endogenous polymerase to "fill-in" the partially single-stranded region, thus allowing detection of HBV replication and viais production
- Huh7 cells, co-tiansfected with pGEM-HBV-overlength and pLNT-Rz DNA were lysed with EPA Lysis Buffer (50 M Tris, pH 7 5, 40 mM NRtCl, 15 mM MgCI 2 , 1 % NP-40, 0 3% ⁇ -mercaptoethanol) for 30 minutes on ice Lysates were centrifuged at 14,000 x g for 10 minutes at 4°C and HBV core particles in the supern
Abstract
This invention provides ribozymes useful to treat or prevent Hepatitis B Virus ('HBV') infection in an organism or subject, as well as methods of treating an HBV infection. Reagents such as vectors, host cells, DNA molecules coding for these ribozymes useful in methods of treatment and prevention of HBV infection also are provided.
Description
Description
RIBOZYME THERAPY FOR HEPATITIS B INFECTIONS
Technical Field
The present invention relates generally to therapeutics, and more specifically, to compositions and methods which utilize ribozymes in the treatment of Hepatitis B infections
Background ofthe Invention
Hepatitis B viral ("HBV") infection remains a worldwide health problem, with estimates of over 300 million chronically infected individuals The Center for Disease Control ("CDC") estimates that there are approximately 1 million carriers in the United States and over 300,000 new infections per year Chronic HBV infection is a major cause of liver cirrhosis. HBV infection also is associated with one of the most common visceral malignancies worldwide, primary hepatocellular carcinoma In areas of the world where HBV infection is endemic, hepatocellular carcinoma ("HCC") is among the most common lethal malignancies.
Hepatocellular carcinoma is a rapidly fatal tumor unless curative hepatic resection is possible. Unfortunately, most patients with HBV and HCC are cirrhotic and resection is contraindicated Chemotherapy also has proven to be ineffective. Chemoembolization has shown some recent promise in uncontrolled trials Orthotopic liver transplantation ("OLT") has been performed for HCC, but the long term survival is less than 25%. Many centers have abandoned orthotopic liver transplantation to treat hepatocellular carcinoma because of the poor outcome and the obligate loss of the donated organ at this time, when there are two suitable recipients for every donor organ Alpha 2b interferon has been successfully used to treat chronic HBV infection in adults and is now being studied in children Prognostic indicators of
success include a low rate of viral replication and a substantial elevation of serum aminotransferase enzymes. In chronic carriers and patients with modest aminotransferase enzyme elevations, however, treatment is usually unsuccessful. Interferon is also ineffective in immunosuppressed patients with recurrent HBV infection post-OLT. Thus, a need exists for an effective treatment to combat HBV infection. This invention satisfies this need and provides related advantages as well.
Summary ofthe Invention
The present invention provides ribozymes useful to treat or prevent Hepatitis B Virus ("HBV") infection in an organism or subject, as well as methods of treating an HBV infection. Reagents such as vectors, host cells, DNA molecules coding for these ribozymes useful in methods of treatment and prevention of HBV infection also are provided.
Accordingly, in one aspect the present invention provides ribozymes having the ability to inhibit replication and infectivity of a hepatitis B virus. Preferably, the ribozyme is a hammerhead or hairpin ribozyme, representative examples of which recognize the sequences set forth in Table I , below. In preferred embodiments, the present invention also provides a nucleic acid molecule encoding such ribozymes; further preferably, the nucleic acid is DNA or cDNA Even further preferably, the nucleic acid molecule is under the control of a promoter to transcribe the nucleic acid.
In another aspect, the present invention provides host cells containing the ribozymes described herein, vectors comprising the nucleic acid encoding the ribozymes descπbed herein, and host cells comprising such a vector. Preferably, the vector is a plasmid, a virus, retrotransposon, a cosmid or a retrovirus. In one embodiment where the vector is a retroviral vector, the nucleic acid molecule encoding the ribozyme under the control of a promoter, which is preferably a pol III promoter, further preferably a human tRNAVnl promoter or an adenovirus VA1 promoter, is inserted between the 5' and 3' long terminal repeat sequences of the retrovirus. The present invention also provides a host cell stably transformed with such a retroviral vector. Preferably, the host cell is a murine or a human cell.
In a further aspect, the present invention provides methods for producing a ribozyme, the ribozyme being able to inhibit hepatitis B viral infection and replication in a cell, which method comprises providing a nucleic acid molecule (e.g., DNA) encoding the ribozyme under the transcriptional control of a promoter, and transcribing the nucleic acid molecule to produce the ribozyme. Preferably, the method further comprises purifying the ribozyme produced. The ribozyme may be produced /'/; vitro, in vivo or ex vivo.
In yet another aspect, the present invention provides methods of interfering with or preventing HBV replication in a cell infected with HBV, which method comprises introducing into the cell an effective amount of the ribozymes described herein. In one embodiment, such methods comprise introducing into the cell an effective amount of DNA encoding a ribozyme as described herein and transcribing the DNA to produce the ribozyme. Preferably, the cell is a human cell.
In still a further aspect, the present invention provides methods of preventing hepatitis B viral infection in a cell susceptible to infection with HBV, which methods comprise introducing into the cell an effective amount of a nucleic acid molecule (e.g., DNA) encoding a ribozyme as described herein and transcribing the
DNA to produce the ribozyme. Preferably, the cell is a human cell.
In preferred embodiments, the methods further comprise administering the cell transduced with a retroviral vector to a mammal of the same species as that from which the transduced cell was obtained. In other preferred embodiments, the cell transduced with the retroviral vector has been obtained from the mammal receiving the transduced cell.
These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein that describe in more detail certain procedures or compositions (e.g., plasmids, etc.), and are therefore incorporated by reference in their entirety as if each were individually noted for incorporation.
Brief Description ofthe Drawings
Figure 1 is a schematic illustration of vector pLNT-Rz Figures 2A, 2B, 2C and 2D are schematic representations of HBV and ribozyme expression vectors, and wild type and tetraloop hairpin ribozyme structures. Figure 2A discloses "overlength" HBV as cloned into pGem7 The pre-genomic RNA (pgRNA) start site and common polyA signal are indicated. All RNA transcripts are driven by authentic HBV promoters Cleavage sites for hairpin ribozymes BR1, BR2 and BR3 are indicated by downward arrows HBV-encoded proteins X, C (core), S (envelope) and P (polymerase) are shown as boxes below Figure 2B discloses a ribozyme in the retroviral vector pLNT-Rz, which is used for ribozyme expression in mammalian cells Briefly, ribozymes are cloned under the control of the human tRNAval promoter ("LTR" Moloney Long Terminal Repeat) In Figure 2C, the hairpin ribozyme consists of a 50 to 54 nucleotide RNA molecule (shaded, in uppercase letters) which binds and cleaves an RNA substrate (lowercase letters). The catalytic RNA folds into a 2-dimensional structure that resembles a hairpin, consisting of two helical domains (Helix 3 and 4) and 3 loops (Loop 2, 3 and 4). Two additional helixes, Helix 1 and 2, form between the ribozyme and its substrate Recognition of the substrate by the ribozyme is via Watson-Crick base pairing (where N or n = any nucleotide, b = C, G or U and B = the nucleotide complementary to b) The length of Helix 2 is fixed at 4 basepairs and the length of Helix I typically varies from 6 to 10 basepairs, with 8 being experimentally optimal for most ribozymes. The substrate must contain a GUC in Loop 5 for maximal activity, and cleavage occurs immediately 5' of the G as indicated by an arrow. The catalytic, but not substrate binding, activity of the ribozyme can be disabled by mutating the AAA in Loop 2 to CGU, as shown. The tetraloop hairpin ribozyme (Figure 2D) differs from the hairpin ribozyme by replacement of Loop 3 and Helix 4 with the RNA-stabilizing tetraloop configuration.
Figure 3 depicts the results of n vitro cleavage experiments of HBV RNA by BR1 and BR3 ribozymes Ribozymes BR1 and BR3, as well as their disabled counterparts, dBR l and dBR3 were tested Briefly, ribozymes and radiolabeled HBV substrate were synthesized by /// vitro transcription. HBV substrates are as follows BR1 substrate = HBV nucleotides 1629- 1919 (pgRNA start site is nucleotide 1 ),
generated from EcoNΪ-linearized pGem-HBV-X/B, BR3 substrate = HBV nucleotides 2782-3023, generated from EcoNI-linearized pGem-HBV-B/E Cleavage reactions contain 40 nM ribozyme and 200 nM substrate (ribozyme. substrate = 1 5) and were incubated for 0 or 60 minutes at 37°C Cleavage products were resolved on 5% polyarcylamide/7M urea gels Uncleaved substrate and the 5' and 3' cleavage products are indicated
Figures 4A and 4B depicts the results of n vitro kinetic studies for BRl and tetraloop BRl (Figure 4 A), and BR3 and tetraloop BR3 (Figure 4B) Shown are typical in vitro cleavage reaction timecourse experiments, including 5 2 nM ribozyme and 72 nM substrate The reactions were incubated at 37°C and aliquots were removed every 30 minutes fiom 0 to 120 minutes, as indicated Cleavage products were quantitated by phosphorimager analyses
Figures 5A and 5B show ribozyme expression /// vitro verified by RNase protection Briefly, in Figure 5 A Huh7 cells were transfected with each of the ribozymes indicated Twenty-five micrograms of total cellular RNA was hybridized to 128 nucleotide radiolabeled probes, of equal, specific activity, antisense to either BRl or BR3, as indicated Following RNase digestion, reactions were electrophoresed on a 8% polyacrylamide/7M urea gel and quantitated by phosphorimager analysis. Due to the three nucleotide difference between the active and the disabled form of each ribozyme, the expected protected fragments are 64 nt for BR l and BR3, and 32 nt + 29 nt for dBR l and dBR3 (see panel 5B for schematic representation of protected fragments)
Figures 6A and 6B show that expression of anti-HBV ribozymes reduces Hepatitis B virus production in liver cell culture Briefly, Huh7 cells were co- transfected with overlength HBV and pLNT-Rz for each ribozyme The DNA molar ratio for HBV ribozyme ranged from I 5 to 1 20, as indicated Three days post transfection, cells were lysed and HBV particles were immunoprecipitated for the endogenous polymerase assay. Figure 6A shows a typical endogenous polymerase assay with radiolabeled HBV DNA resolved by agarose gel electrophoresis, with relaxed circular (R C ) and linear forms indicated Figure 6B shows quantitation as performed by phosphorimager analysis Values are pixel volumes generated following
phosphorimager scanning. Percentages listed above graph bars indicate percent reduction of HBV production by each ribozyme, relative to HBV transfections without ribozyme (first bar on graph).
Detailed Description ofthe Invention
DEFINITIONS Prior to setting forth the invention, it may be helpful to an understanding thereof to first set forth definitions of certain terms that will be used hereinafter.
"Ribozyme" refers to a nucleic acid molecule which is capable of cleaving a specific nucleic acid sequence. Ribozymes may be composed of RNA, DNA, nucleic acid analogues (e.g., phosphorothioates), or any combination of these (e.g., DNA/RNA chimerics). Within particularly preferred embodiments, a ribozyme should be understood to refer to RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic activity
"Ribozyme gene" refers to a nucleic acid molecule (e.g., DNA) consisting of the ribozyme sequence which, when transcribed into RNA, will yield the ribozyme. "Vector" refers to an assembly which is capable of expressing a ribozyme of interest. The vector may be composed of either deoxyribonucleic acids ("DNA") or ribonucleic acids ("RNA"). Optionally, the vector may include a polyadenylation sequence, one or more restriction sites, as well as one or more selectable markers such as neomycin phosphotransferase, hygromycin phosphotransferase or puromycin-N-acetyl-transferase. Additionally, depending on the host cell chosen and the vector employed, other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences conferring inducibility of transcription, and selectable markers, may also be incorporated into the vectors described herein.
As noted above, the present invention provides ribozymes which are capable of cleaving Hepatitis B viral nucleic acids. Briefly, the viral genome of HBV is about 3000 to 3300 nucleotides in length. Although the viral DNA is circular, both strands of the viral duplex are linear, and the circular conformation is maintained by extensive base-pairing between the two gapped DNA strands. The negative strand of the virus is about 3200 nucleotides in length while the positive strand is shorter, due to single-stranded gaps of variable size. Upon infection, the HBV DNA polymerase in the nucleocapsid core is activated and completes the synthesis of the positive strand, using the negative strand as a template. These features of the genome structure have suggested a retrovirus-like pathway of virus replication
After conversion of the gapped double stranded DNA to fully double stranded DNA, a full-length positive-strand RNA is transcribed from the DNA template. It is believed that this pregenome RNA is packaged within the cell to form an "immature core," and by reverse transcription, a DNA strand of negative polarity is synthesized. This step is followed by the synthesis of a partial positive strand and the full maturation of the virus particle containing a gapped DNA genome. However, it is the pregenome RNA and the mRNA of the virus which is the target of the ribozymes of this invention. Successful inhibition at this stage in the viral cycle can potentially eliminate hepatic and extrahepatic replication and transmission in all infected patients, including chronic carriers. An additional benefit is the prevention of Hepatitis D viral infection which require HBsAg as its envelope.
RlHOZY I- S
As noted above, the present invention provides ribozymes having the ability to inhibit replication, infectivity, or gene expression of a hepatitis B viral infection in a cell. Several different types of ribozymes may be constructed for use within the present invention, including for example, hammerhead ribozymes (Rossi, J.J. et al., Pharmac. Ther. 50:245-254, 1991 ) (Forster and Symons, Cell - <*?:21 1-220, 1987; Haseloff and Gerlach, Nature 328:596-600, 1988; Walbot and Bruening, Nature 334 96, 1988; Haseloff and Gerlach, Nature 33-/-.5S5, 1988; Haseloff et al., U.S. Patent No. 5,254,678), hairpin ribozymes (Hampel et al., Nucl. Acids Res.
75:299-304, 1990, and U.S Patent No. 5,254,678), hepatitis delta virus ribozymes (Perrotta and Been, Biochem. 37. 16, 1992), Group I intron ribozymes (Cech et al., U.S. Patent No. 4,987,071) RNase P ribozymes (Takada et al.. Cell 35:849, 1983); (see e.g., WO 95/29241 , entitled "Ribozymes with Product Ejection by Strand Displacement"; and WO 95/3 1551 , entitled "Novel Enzymatic RNA Molecules."
Cech et al. (U.S. Patent No. 4,987,071 , issued January 22, 1991) has disclosed the preparation and use of certain synthetic ribozymes which have endoribonuclease activity These ribozymes are based on the properties of the Tetrahymena ribosomal RNA self-splicing reaction and require an eight base pair target site with a requirement for free guanosine or guanosine derivatives A temperature optimum of 50°C is reported for the endoribonuclease activity The fragments that arise from cleavage contain 5'-phosphate and 3'-hydroxyl groups and a free guanosine nucleotide added to the 5'-end of the cleaved RNA In contrast, the ribozymes of this invention hybridize efficiently to target sequences at physiological temperatures, making them suitable for use in vivo, not merely as research tools (see column 15, lines 18 to 42, of Cech et al , U.S Patent No 4,987,071 ).
Particularly preferred ribozymes for use within the present invention are hairpin ribozymes (for example, as described by Hampel et al., European Patent Publication No 0 360 257, published March 26, 1990) Briefly, the sequence requirement for the hairpin ribozyme is any RNA sequence consisting of NNNBN*GUC(N) (Sequence ID Nos. 1-5) (where x is any number from 6 to 10, N*G is the cleavage site, B is any of G, C, or U, and N is any of G, U, C, or A). Representative examples of recognition or target sequences for hairpin ribozymes are set forth below in the Examples. Additionally, the backbone or common region of the haiφin ribozyme can be designed using the nucleotide sequence of the native hairpin ribozyme (Hampel et al., Nncl. Acid.s Res. 18 299-304, 1990) or it can be modified to include a "tetraloop" structure that increases stability and catalytic activity (see Example 2 and Figure 3; see also Yu et al , Virology 2f :38 I -386, 1995, Cheong et al., Nature 3- 6:680-682, 1990, Anderson et al , Nitcl. Acids Res. 22: 1096-1 100, 1994). The sequence requirement at the cleavage site for the hammerhead ribozyme is any RNA sequence consisting of NUX (where N is any of G, U, C, or A and X
represents C, U, or A) can be targeted. Accordingly, the same target within the hairpin leader sequence, GUC, is useful for the hammerhead ribozyme The additional nucleotides of the hammerhead ribozyme or hairpin ribozyme is determined by the target flanking nucleotides and the hammerhead consensus sequence (see Ruffner et al.. Biochemistry 29: 10695- 10702, 1990).
Given the disclosure provided herein, along with published sequences of the HBV genome and of RNA encoding the surface antigen of HBV, ribozymes of the present invention may be readily constructed Appropriate base changes in the ribozyme are made to maintain the necessary base pairing with the target HBV sequences. The sequence ofthe HBV is well known to those of skill in the art and can be obtained from GenBank (i.e., accession numbers V00866, J02201, X00715, for HBV ADW), as well as other sources.
The ribozymes of this invention, as well as DNA encoding such ribozymes and other suitable nucleic acid molecules, described in more detail below, can be chemically synthesized using methods well known in the art for the synthesis of nucleic acid molecules (see e.g., Heidenreich et al., J. FASEB 70( l ):90-6, 1993; Sproat, Curr. Opin. Biotechnol. - ( l ):20-28, 1993), . Alternatively, Promega, Madison, Wis., USA, provides a series of protocols suitable for the production of nucleic acid molecules such as ribozymes. Within other aspects of the present invention, ribozymes can also be prepared from a DNA molecule or other nucleic acid molecule (which, upon transcription, yields an RNA molecule) operably linked to an RNA polymerase promoter, e.g., the promoter for T7 RNA polymerase or SP6 RNA polymerase. Accordingly, also provided by this invention are nucleic acid molecules, e.g., DNA or cDNA, coding for the ribozymes of this invention When the vector also contains an RNA polymerase promoter operably linked to the DNA molecule, the ribozyme can be produced ;'/; vitro upon incubation with the RNA polymerase and appropriate nucleotides. In a separate embodiment, the DNA may be inserted into an expression cassette, such as described in Cotten and Birnstiel, EMBO .1. Λ'( 12):3861 -3866, 1989, and in Hempel et al.. Biochemistry 2<S':4929-4933, 1989. A more detailed discussion
of molecular biology methodology is disclosed in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, 1989
During synthesis, the ribozyme can be modified by ligation to a DNA molecule having the ability to stabilize the ribozyme and make it resistant to RNase (Rossi et al., Pharn ac. Ther. 50.245-254, 1991 ) Alternatively, the ribozyme can be modified to the phosphothio analog for use in liposome delivery systems This modification also renders the ribozyme resistant to endonuclease activity
VΓCTORS Use of ribozymes to treat HBV infection involves introduction of functional ribozyme to the infected cell of interest This can be accomplished by either synthesizing functional ribozyme in vitro prior to delivery, or, by delivery of DNA capable of driving ribozyme synthesis /// vivo
More specifically, within other aspects of the invention the ribozyme gene may be constructed within a vector which is suitable for introduction to a host cell (e.g., prokaryotic or eukaryotic cells in culture or in the cells of an organism). Appropriate prokaryotic and eukaryotic cells can be transfected with an appropriate transfer vector containing the nucleic acid molecule encoding a ribozyme of this invention. To produce the ribozymes with a vector /// vivo, nucleotide sequences coding for ribozymes are preferably placed under the control of a eukaryotic promoter such as pol III (e.g., tRNA or VA- 1 from adenovirus), CMV, SV40 late, or SV40 early promoters. Within certain embodiments, the promoter may be a tissue-specific promoter such as, for example, a liver-specific promoter such as the albumin promoter and the alphafetoprotein promoter (Feuerman et al , Mol. Cell. Biol. 9 4204-12, 1989; Camper and Tilghman, denes Develop. 3 537-46, 1989), the alcohol dehydrogenase promoter (Felder, Proc. Natl. Acad. Sci. USA 86 5903-07, 1989), the Apolipoprotein B gene promoter (Das et al , J. Biol. Chem 263 1 1452-8, 1988), the Coagulation protease factor VII gene promoter (Erdmann et al , J. Biol. Chem. 270.22988-96, 1995); the Fibrinogen gamma gene promoter (Zhang et al , J. Biol. Chem. 270.24287- 91, 1995); the Glucokinase gene promoter (Williams et al , Biochem. Biophys., Res.
Comm. 212 272-9, 1995), the Liver phosphofructokinase gene promoter (Levanon et al., Biochem. Mol. Biol. Int 35 729-36, 1995), the Phospho-Enol-Pyruvate Carboxy- Kinase ("PEPCK") promoter (Hatzogiou et al , J. Biol. Chem. 263: 17798-808, 1988, Benvenisty et al., Proc. Nail. Acad. Sci. USA 86 1 1 18-22, 1989, Vaulont et al., Mol. Cell. Biol. 9 4409- 15, 1989), or lymphoid-specific promoters Ribozymes may thus be produced directly from the transfer vector /// vivo
A wide variety of vectors may be utilized within the context of the present invention, including for example, plasmids, viruses, retrotransposons and cosmids Because HBV infects the liver, vectors with hepatotrophic properties are particularly preferred Representative examples include adenoviral vectors (e.g. , WO 94/26914, WO 93/9191 , Yei et al , dene Therapy I 192-200, 1994, Kolls et al , PNAS 97(1 ) 215-219, 1 94, Kass-Eisler et al , PNAS 90(24) 1 1498-502, 1 93, Guzman et al . Circulation 88(6) 2838-48, 1993, Guzman et al , Cn: Res. 73(6) 1202- 1207, 1993, Zabner et al , Cell 75(2).207-216, 1993, Li et al , Hum Gene Ther. 4(4) 403- 409, 1993, Caillaud et al , /•;///-. J Neitrosci. 5( 10) 1287-1291 , 1993), adeno- associated type 1 ("AAV- 1 ") or ade o-associated type 2 ("AAV-2") vectors (.see WO 95/13365, Flotte et al , PNAS 90(22) 10613- 10617, 1993), hepatitis delta vectors, live, attenuated delta viruses and herpes viral vectors (e.g., U S Patent No 5,288,641), as well as vectors which are disclosed within U S Patent No 5, 166,320 Other representative vectors include retroviral vectors (e.g., EP 0 415 731 , WO 90/07936; WO 91/02805, WO 94/03622, WO 93/25698, WO 93/25234, U S Patent No 5,219,740, WO 93/1 1230, WO 93/10218) For vectors without inherent hepatotropism (e.g., AAV or retroviruses), cell tropism can be altered to specifically target these viruses to the liver Methods of using such vectors in gene therapy are well known in the art, see, for example, Lai rick, J W and Burck, K L , Gene Therapy: Application of Molecular Biology, Elsevier Science Publishing Co , Ine , New York, New York, 1991 and Kreigler, M , Gene Transfer and Expression: A Laboratory Manual, W H Freeman and Company, New York, 1990
Further provided by this invention are vectors having more than one nucleic acid molecule encoding a ribozyme of this invention, each molecule under the control of a separate eukaryotic promoter or alternatively, under the control of single
eukaryotic promoter. Representative examples of other therapeutic molecules which may be delivered by the vectors ofthe present invention include interferon (e.g., alpha, beta or gamma), as well as a wide variety of other cytokines or growth factors. These vectors provide the advantage of providing multi-functional therapy against HBV infection, preferably with the various therapies working together in synergy.
Host prokaryotic and eukaryotic cells stably harboring the vectors described above also are provided by this invention Suitable host cells include bacterial cells, rat cells, mouse cells, and human cells, for example, liver and blood cells.
DHI.IVHRY Within certain aspects of the invention, ribozyme molecules, or nucleic acid molecules which encode the ribozyme, may be introduced into a host cell utilizing a vehicle, or by various physical methods Representative examples of such methods include transformation using calcium phosphate precipitation (Dubensky et al., PNAS 57:7529-7533, 1984), direct microinjection of such nucleic acid molecules into intact target cells (Acsadi et al.. Nature 352:81 -818, 1991 ), and electroporation whereby cells suspended in a conducting solution are subjected to an intense electric field in order to transiently polarize the membrane, allowing entry of the nucleic acid molecules. Other procedures include the use of nucleic acid molecules linked to an inactive adenovirus (Cotton et al., PNAS Λ'9:6094, 1990), lipofection (Feigner et al., Proc. Nail. Acad. Sci. USA 84.7413-7417, 1989), microprojectile bombardment (Williams et al., PNAS Λ7?:2726-2730, 1991 ), polycation compounds such as polylysine, receptor specific ligands, liposomes entrapping the nucleic acid molecules, spheroplast fusion whereby E. coli containing the nucleic acid molecules are stripped of their outer cell walls and fused to animal cells using polyethylene glycol, viral transduction, (Cline et al., Pharmac. Ther. 29:69, 1985; and Friedmann et al.. Science 244: 1275, 1989), and DNA ligand (Wu et al, J. of Biol. Chem. 2r : 16985- 16987, 1989). In one embodiment, the ribozyme is introduced into the host cell using a liposome.
PHΛRMΛCF.I ΓTICΛI . >MI*< >SITK >NS As noted above, pharmaceutical compositions also are provided by this invention. These compositions contain any of the above described ribozymes, DNA molecules, vectors or host cells, along with a pharmaceutically or physiologically acceptable carrier, excipients or diluents. Generally, such carriers should be nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the therapeutic agent with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrins, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with nonspecific serum albumin are exemplary appropriate diluents. In addition, the pharmaceutical compositions of the present invention may be prepared for administration by a variety of different routes, including for example intraarticularly, intracranially, intradermally, intrahepatically, intramuscularly, intraocularly, intraperitoneally, intrathecally, intravenously (e.g., into the portal vein), or subcutaneously. In addition, pharmaceutical compositions of the present invention may be placed within containers, along with packaging material which provides instructions regarding the use of such pharmaceutical compositions. Generally, such instructions will include a tangible expression describing the reagent concentration, as well as within certain embodiments, relative amounts of excipient ingredients or diluents (e.g., water, saline or PBS) which may be necessary to reconstitute the pharmaceutical composition
TH.'RΛPΠI π IC MI-:TI K >DS Methods of interfering with or preventing HBV viral replication, infectivity, or gene expression in a cell infected with HBV are also provided by this invention. Such methods require contacting the cell with an effective amount of
ribozyme of this invention or, alternatively, by transducing the cell with an effective amount of vector having a nucleic acid molecule encoding the ribozyme. Effective amounts are easily determined by those of skill in the art using well known methodology. When exogenously delivering the ribozyme, the RNA molecule can be embedded within a stable RNA molecule or in another form of protective environment, such as a liposome. Alternatively, the RNA can be embedded within RNase-resistant DNA counterparts. Cellular uptake of the exogenous ribozyme can be enhanced by attaching chemical groups to the DNA ends, such as cholesteryl moieties (Letsinger et al , /'.N.Λ.Λ'., U.S.A., 1989) In another aspect of the invention, (he target cell is transduced under conditions favoring insertion of the vector into the target cell and stable expression of the nucleic acid encoding the HBV specific ribozyme. The target cell can include but is not limited to hepatocytes and lymphocytes If the cell is transduced prior to HBV infection, infection of the target cell or its progeny can be prevented. Accordingly, this aspect includes methods for interfering with or preventing HBV viral infection and/or replication in a cell by reacting the target RNA sequence with a ribozyme of this invention
In one embodiment of this aspect of the invention, appropriate host cells such as liver cells are removed from a subject, e.g., a human patient, using methods well known in the art. The cells are then trypsinized and resuspended for ex vivo therapy. Within the cell or within the cells of an organism, a transfer vector as described above encoding one or more ribozymes is transfected into a cell or cells using methods described in Llewellyn et a!., . Mol. Biol. 195: 1 15-123, 1987, and Hanahan, 7o7>:557-580, 1983. Inside the cell, the transfer vector replicates and the DNA coding for the ribozyme is transcribed by cellular polymerases to produce ribozymes which then inactivate HBV Mici manipulation techniques such as microinjection also can be used to insert the vector into the cell so that the transfer vector or a part thereof is integrated into the genome of the ceil Transcription of the integrated material gives rise to ribozymes which then inactivate HBV. The above methods are not intended to limit the invention, but merely to exemplify various means
to effect the ribozyme therapy of this invention Other methods are detailed in Anderson, Science 256:808-813, 1992.
For ex vivo therapy, the transduced cells can be reintroduced into the patient by hepatic artery injection under conditions such that the transduced cells will integrate into the liver.
As used herein, the term "interfering with or preventing" HBV viral replication in a cell means to reduce HBV replication or production of HBV components necessary for progeny virus in a cell as compared to a cell not being transiently or stably transduced with the ribozyme or a vector encoding the ribozyme. Simple and convenient assays to determine if HBV viral replication has been reduced include an ELISA assay for the presence, absence, or reduced presence of anti-HBV antibodies or hepatitis B antigens in the blood of the subject, RT-PCR or liver function tests. Such methods are well known to those of ordinary skill in the art. Alternatively, total RNA from transduced and infected "control" cells can be isolated and subjected to analysis by dot blot or northern blot and probed with HBV specific DNA to determine if HBV replication is reduced. Alternatively, reduction of HBV protein expression can also be used as an indicator of inhibition of HBV replication. A greater than fifty percent reduction in HBV replication as compared to control cells typically quantitates a prevention of HBV replication.
The following examples are offered by way of illustration, and not by way of limitation.
EXAMPLES
EXAMPLE I
CRITERIA FOR HAIRPIN RIBOXYMI SΓΠ: SELECTION
Hairpin ribozymes suitable for use within the present invention preferably recognize the following sequence of HBV RNA. NNNBN*GUC(N)X (Sequence ID No. 1) (where x is any number from 6 to 10, N*G is the cleavage site, B is any of G, C, or U, and N is any of G, U, C, or A) The sequence GUC must be conserved for all hairpin ribozymes described below Other nucleotides ("N" as provided above) preferably have a high degree of sequence conservation in order to limit the need for multiple ribozymes against the same target site GUC hairpin ribozyme recognition sites for HBV are provided below in Table 1.
Table 1
Hairpin Ribozyme Recognition Sites in Human Hepatitis B HBV adw subtype (Numbered from unique EcoRI site)
NUCLEOTIDE POSITION
SEQUENCE (5' to 3' ) NAME Seq. ID No.
311 UCGCA"GUCCCCAACCU BRl 2
343 CUCCU"GUCCUCCAAUU 3
651 CCUCA"GUCCGUUUCUC 4
1303 AGCCG"GUCUGGAGCAA 5
1337 AUUCU'GUCGUCCUCUC 6
1429 GUCCC'GUCGGCGCUGA BR2 ( no cleavage ) 7
1494 UCUCC"GUCUGCCGUUC 8
1538 ACGCG~GUCUCCCCGUC 9
1546 UCCCC"GUCUGUGCCUU BR3 10
1568 UGCCG~GUCCGUGUGCA 11
3127 CGGCA~GUCAGGAAGGC 12
3171 AGACA"GUCAUCCUCAG 13
CONSENSUS NNNCN'GUCNNNNNNNN (12 total)
SEQUENCE (5- to 3* ) Sect. ID No.
113 AUCUC"GUCAAUCUCCG 14
355 AAUUU"GUCCUGGUUAU 15
469 CGUUU~GUCCUCUAAUU 16
611 CCAUC"GUCCUGGGCUU 17
811 CUUUU'GUCUCUGGGUA 18
1151 CUGUC"GUCCUCUCGCG 19
1164 GCCUG GUCUGUGCCAA 20
1482 CUCUC*GUCCCCUUCUC 21
1792 AAUUG"GUCUGCGCACC 22
2151 UAGUA~GUCAAUUAUGU 23
2253 AUUUG~GUCUCUUUCGG 24
CONSENSUS NNNUN'GUCNNNNNNNN (11 total)
SEQUENCE (5' to 3" ) Seq. ID No.
33 CCAGA"GUCAGGGGUCU 25
40 CAGGG~GUCUGUAUCUU 26
241 GCAGA"GUCUAGACUCG 27
292 CGUGU'GUCUUGGCCAA 28
301 CGUGA"GUCCCUUUAUA 29
376 GAUGU"GUCUGCGGCGU 30
999 UGUGG"GUCUUUUGGGC 31
2024 UUAGA"GUCUCCUGAGC 32
2351 UGCGG'GUCACCAUAUU 33
2416 GCCGC"GUCGCAGAAGA 34
2582 UAGGU 'GUCAACAAUUU 35
2951 ACAGU'GUCAACAAUUC 36
CONSENSUS NNNGN'GUCNNNNNNNN (12 total)
EXAMPLE 2
CONSTRl JCTION OF HAIRPIN RIBOZYMES
Two single-stranded DNA oligonucleotides are chemically synthesized such that, when combined and converted into double-stranded DNA, they contain the entire hairpin ribozyme, including nucleotides complementary to the target site. In addition, restriction enzyme recognition sites may be placed on either end to facilitate subsequent cloning. For example, in order to construct ribozyme BR3:
5 * -<_α3GAT03 AGGG^^ '
Restriction enzyme sites are in bold. Sequences complementary to the BR3 target site in HBV are underlined.
Briefly, the indicated oligonucleotides are hybridized together and converted to double-stranded DNA using either Klenow DNA polymerase or Taq DNA polymerase. The resulting DNA is cleaved with restriction enzymes BamHI and M Λ, purified and cloned into vectors for /// vitro transcription (pGEM, ProMega, Madison, Wis.) or for retrovirus production and mammalian expression (pLNL/MJT backbone).
Defective or "disabled" ribozymes for use as controls may be constructed as described above, with the exception that the sequence AAA is changed to a UGC as shown in Figure 2.
EXAMPLE 3 IN VITRO CLEAVAGE ASSAYS
Ribozymes are cloned into in vitro transcription vectors (pGEM-7Z, ProMega, Madison, Wis.) and transcribed // vitro by T7 RNA polymerase. Following transcription, reactions are treated with RQ 1 DNase (Promega, Madison, Wisconsin) according to the manufacturer's instructions, and the ribozymes are purified by denaturing polyacrylamide gel electrophoresis.
The full length HBV genome, in pEco63 was obtained from American Type Culture Collection (ATCC Accession Numbers V00866, J02201 and X00715). Plasmids for HBV substrate production were constructed by cloning two HBV fragments into pGem7Z as follows. pGem-HBV-X/B was created by ligating the XbaVBa WΛ fragment of HBV (nucleotides 1629-2782, pgRNA start site = 1 ) into pGem7Z digested with Xbaλ and Ba YW. pGem-HBV-B/E was created by ligating the BamHVEcoRl fragment of HBV (nucleotides 2782-1380, pgRNA start site = 1) into pGem7Z digested with BamH] and EcoKl. Both plasmids were linearized with EcoN prior to /// vitro transcription. HBV substrates were then synthesized in the presence of alpha-'2P[UTP], DNase treated and gel purified, as described by the manufacturer (Promega). The /// vitro cleavage reactions contained 40 nM ribozyme and 200 nM substrate in 12 mM MgCl2/2 mM spermidine/40 mM Tris-HCl, pH 7.5, were incubated at 37°C for 60 minutes and were terminated by the addition of 7M urea gel loading buffer. Products of the cleavage reactions were resolved by electrophoresis on 5% polyacrylamide/7 M urea gels and analyzed by autoradiography. Results are shown in Figure 3. Briefly, ribozymes BRl and BR3 cleaved up to 35% of their substrate RNAs in 60 minutes, under physiological concentrations of magnesium, without any prior treatment or denaturation. As controls, the disabled forms of BRl and BR3 (designated dBRl and dBR3) were also tested. As described above in Example 2, disabled ribozymes are made by introducing a three nucleotide mutation in loop 2 of the hairpin ribozyme. This inactivates its RNA cleavage activity, without affecting its substrate binding. Neither dBRl nor
dBR3 showed any RNA cleavage activity (lanes 4 and 8), indicating that the cleavage demonstrated by BRl and BR3 is specific Ribozyme BR2, however, showed no in vitro cleavage activity after 60 minutes (data not shown). Since both the BR2 ribozyme and its substrate target site were verified by DNA sequencing, the lack of cleavage activity was presumably due to RNA secondary structure within the substrate.
EXAMPLE 4 R ozYME KINETIC STUDIES
A. Preparation of ribozymes and substrates
Ribozyme and substrate synthesis was achieved by plasmid independent /// vitro transcription. Briefly, oligonucleotides were synthesized (Retrogen, San Diego) that contained the T7 RNA polymerase promoter and the ribozyme or substrate sequences. The universal T7 promoter oligo contains 63 nucleotides of random sequence ("template arm") and 17 nucleotides that make up the T7 promoter. The ribozyme oligo contains the 17 nucleotides complementary to the T7 promoter followed by a CCC (for optimal transcription) and the 50 bases encoding the ribozyme. Similarly, the substrate oligos contain the T7 promoter, a CCC and the 33 or 34 nucleotides encoding the substrate. To synthesize each ribozyme or substrate the two oligonucleotides were annealed and converted to double-stranded DNA using Klenow polymerase. n vitro transcription was carried using 4 μg of dsDNA template at 37°C for 2 hours using T7 RNA polymerase (Promega), according to the manufacturer's instructions. RNAs were labeled by incorporation of alpha P-CTP during the transcription reaction and purified by denaturing gel electrophoresis.
(b) /// Vitro Cleavage Reactions. Time course reactions were prepared in a final volume of 25 μl with a ribozyme concentration of 0.0052 μM and substrate concentration of 0.072 μM. The
reactions were assembled on ice and 5 μl was removed for the 0 min time point and mixed with 5 μl loading buffer and stored at -85°C The remainder of the reaction was incubated at 37°C for up to 2 hr in 40 mM Tris pll 7.5, 10 mM MgCl2 mM spermidine, with timepoints being taken every 30 minutes Five microliters of reaction was removed for each time point and mixed with loading buffer as above Reaction products were analyzed by urea denaturing polyacrylamide gel electrophoresis (PAGE) and cleavage products were quantitated by phosphorimager analysis (Molecular Dynamics) Percent cleavage was defined as (radioactivity of the products)/[(radioactivity ofthe products) + (radioactivity of remaining substrate)] The Michaelis constant (K,„) and kc.„ were also determined for each of the ribozymes by performing multiple turnover kinetic experiments Briefly, kinetic reactions were assembled on ice in a final volume of 10 μl Ribozyme concentration was held constant at either 2 or 4 nM and substrate concentrations ranged from 2 to 200 nM. Reactions were incubated at 37°C for as little as 15 minutes for the fastest reactions and up to an hour for the slowest reactions Cleavage reactions were done in the same buffer as described above and reactions were terminated by the addition of 10 μl of loading buffer Products were resolved by urea denaturing PAGE and analyzed as above The Km and k l, for the ribozymes were estimated from plotting the data in an Eadie Ho stee plot (Deltagraph, Deltapoint Ine ) with R2 >0 90 The error repeated experiments <20% Catalytic efficiency = kCJ,/Km = IO4 min"1 M"1
Results are shown in Figure 4 Briefly, by performing cleavage timecourse experiments using each ribozyme, it was revealed that in both cases the addition of a tetraloop enhanced cleavage activity To determine if the tetraloop affected Kn„ k„, or both, kinetic studies were performed by holding the ribozyme concentration constant while varying the amount of substrate By plotting this information in an Eadie-Hofstee plot, Km and ,3, can be determined, and the values for each ribozyme are shown under the graphs For BR l and BR3, the tetraloop increased the catalytic efficiency 3- to 7.5-fold, respectively, over that of the unmodified ribozyme In both cases, addition of a tetraloop mainly enhanced kca), while having only a modest to insignificant impact on K,„
EXAMPLE 5 CONSTRUCTION AND TESTING or- HBV RIBO/.YME MAMMALIAN EXPRESSION
VEC IX )RS
A. Construction of Vectors
Plasmid pMJT (Yu et al., Proc. Nat 'I Acad. Sci. USA 90:6340-6344, 1993), which contains the anti-U5 HIV ribozyme driven by the tRNA*"' RNA pol III promoter, is digested with BamHI and Mlu\, and the vector purified from the ribozyme fragment.
The "overlength" HBV plasmid was constructed by ligating two HBV DNA fragments into pGEM7Z (Promega). The 5' end of HBV was supplied by the 1966 bp SphMEco X HBV fragment (nucleotides 2614- 1380, pgRNA start site = 1), and the T portion of HBV consisted of the 1988 bp Eco \IBg\\\ HBV fragment (nucleotides 1380-166). A three-way directional ligation was performed wherein the two fragments were ligated into pG7Z digested with Spin and Bam HI). The resulting plasmid, pGEM-HBV-overlength, contains the entire pgRNA and polyA signal, as well as the authentic HBV pgRNA promoter When transfected into human liver cells, this plasmid will express HBV RNA and proteins, resulting in the secretion of infectious hepatitis B viral particles,
B. Cell culture, transfection and ribozyme expression.
Huh7 cells were cultured at 37°C in DMEM (Gibco BRL) supplemented with 10% FBS, L-glutamine, sodium pyruvate and antibiotics. For DNA transfections, 1 x I O6 cells on 100 mm plates were transfected with 1 μg pGEM- HBV-overlength plus 5 to 20 μg pLNT-Rz by standard calcium phosphate transfection procedures, using empty pLNT vector (containing no Rz sequences) to bring the total DNA to 20 μg. One to three days following transfection, ribozyme expression was verified by RNase protection, according to the manufacturer (Promega). Results of this experiment are shown in Figures 5 A and 5B.
C. Endogenous polymerase assay
Quantification of HBV virus particles produced in tissue culture is best achieved using the endogenous polymerase assay (EPA) This assay relies on the fact that the packaged HBV genome is only partially double-stranded and that the HBV- specific polymerase is also packaged in each virion Addition of radiolabeled nucleotide triphosphates to purified HBV particles allows the endogenous polymerase to "fill-in" the partially single-stranded region, thus allowing detection of HBV replication and viais production Briefly, Huh7 cells, co-tiansfected with pGEM-HBV-overlength and pLNT-Rz DNA, were lysed with EPA Lysis Buffer (50 M Tris, pH 7 5, 40 mM NRtCl, 15 mM MgCI2, 1 % NP-40, 0 3% β-mercaptoethanol) for 30 minutes on ice Lysates were centrifuged at 14,000 x g for 10 minutes at 4°C and HBV core particles in the supernatants were subjected to immunoprecipitation with anti-HBcAg polyclonal antibodies (Dako) on proteinA-sepharose beads (Pharmacia) Immunoprecipitates were washed twice with EPA Lysis Buffer and incubated with 50 μCi alpha-dCTP'2 + 100 μM each dATP, dGTP and dTTP at 37°C for 2 hours, with occasional mixing 100 μM cold dCTP was added and the incubation continued for another 1 hour HBV DNA was purified from the intact particles by digestion with Proteinase K (500 μg/ml final) and SDS ( 1 % final) for 2 hours at 37°C followed by phenol extraction and ethanol precipitation Purified DNA was separated on 0 8% agarose gels, dried and analyzed by autoradiography and phosphorimager analysis (Molecular Dynamics)
D Results
The effectiveness of anti-HBV ribozymes as therapeutic agents /// vivo depends on their ability to function in a complex cellular environment Briefly, in order to evaluate the ability of each anti-HBV ribozyme to inhibit HBV replication and production, each pLNT-Rz was co-t ansfected with the "overlength" HBV into Huh7 cells and virus production was monitored by EPA In a typical cotransfection experiment, HBV particles subjected to EPA produce DNA bands representing the
fully-repaired relaxed circular (R C.) form as well as faster migrating linear forms (Figure 6a). When overlength HBV was co-transfected with BR l , HBV production was reduced by up to 77% (Figure 6). Cotransfection with dBRl , however, had no inhibitory effect on HBV replication (lane 6). The lack of an effect by dBR l strongly suggest that the effects of BRl are due to // vivo RNA cleavage and not simply an "antisense" effect, since dBR l maintains a perfect complementary target sequence, but is catalytically inactive. Furthermore, co-transfection with increasing molar amounts of BRl, from 1 :5 to 1 :20 (lanes 5, 4 and 3) resulted in an increasing anti-HBV effect (Figure 6B) indicating a dose-response to the presence of more ribozyme /// vivo. Cotransfection of BR3 with HBV resulted in an 1 1 % reduction in HBV replication (Fig. 6B). While the observed difference between BR l and BR3 activities in vivo correlates with their /'// vitro cleavage activities, the reduced effectiveness of BR3 /'// vivo may further indicate RNA secondary structure in the full length HBV RNAs or the presence of RNA binding proteins at or around the BR3 target site // vivo. Together, these data indicate that both BR l and BR3 HBV ribozymes can function within human cells and further suggest that expression of anti-HBV ribozymes could potentially inhibit HBV replication in infected livers.
From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
Claims
1. A hairpin ribozyme having the ability to inhibit replication and infectivity of a hepatitis B virus.
2. A nucleic acid molecule encoding the ribozyme of claim 1.
3. The nucleic acid molecule of claim 2 wherein the nucleic acid is DNA or cDNA.
4. The nucleic acid molecule of claim 2 under the control of a promoter to transcribe the nucleic acid.
5. A host cell containing the ribozyme of claim 1.
6. A vector comprising the nucleic acid of claim 4
7. A host cell comprising the vector of claim 6.
8. The vector of claim 6 wherein the vector is a plasmid, a virus, retrotransposon or a cosmid.
9. The vector of claim 8 wherein the virus is a retrovirus.
10. The retroviral vector of claim 9 wherein the retrovirus has inserted between the 5' and 3' long terminal repeat sequences of the retrovirus a nucleic acid molecule according to claim 2 under the control of a promoter.
1 1. The retroviral vector of claim 8 wherein the promoter is a pol III promoter.
12. The retroviral vector of claim 1 1 wherein the pol III promoter is the human tRNAVal promoter or the adenovirus VA 1 promoter
13 A host cell stably transformed with the retroviral vector of claim 9
14. The host cell of claim 13 wherein the host cell is a murine or a human cell.
15 A method for producing a ribozyme, the ribozyme being able to inhibit hepatitis B viral infection and replication in a cell, which comprises providing DNA encoding the ribozyme under the transcriptional control of a promoter, transcribing the DNA to produce the ribozyme.
16 The method of claim 15, further comprising purifying the ribozyme produced.
17 The method of claim 15 wherein the ribozyme is produced in vitro
18. The method of claim 15 wherein the ribozyme is produced /// vivo
19. A method of interfering with or preventing hepatitis B virus (HBV) replication in a cell infected with HBV, which comprises introducing into the cell an effective amount ofthe ribozyme of claim I
20 A method of interfering with or preventing hepatitis B virus (HBV) replication in a cell infected with HBV, which comprises introducing into the cell an effective amount of DNA of claim 4 and transcribing the DNA to produce the ribozyme
21 The method of claim 19 or 20 wherein the cell is a human cell.
22. A method of preventing hepatitis B viral infection in a cell susceptible to infection with HBV, which comprises introducing into the cell an effective amount of the DNA of claim 4 and transcribing the DNA to produce the ribozyme.
23. The method of claim 22 wherein the cell is a human cell.
24. The method of claim 22 further comprising administering the cell transduced with the retroviral vector to a mammal of the same species as that from which the transduced cell was obtained.
25. The method of claim 24 wherein the cell transduced with the retroviral vector has been obtained from the mammal receiving the transduced cell.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52125595A | 1995-08-29 | 1995-08-29 | |
US08/521,255 | 1995-08-29 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1997008309A2 WO1997008309A2 (en) | 1997-03-06 |
WO1997008309A3 WO1997008309A3 (en) | 1997-07-10 |
WO1997008309A9 true WO1997008309A9 (en) | 1997-08-14 |
Family
ID=24076029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/013975 WO1997008309A2 (en) | 1995-08-29 | 1996-08-29 | Ribozyme therapy for hepatitis b infections |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1997008309A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0522578D0 (en) * | 2005-11-04 | 2005-12-14 | King S College London | Ribozymal nucleic acid |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1088830A3 (en) * | 1987-06-22 | 2004-04-07 | Medeva Holdings B.V. | Hepatitis b surface antigen particles |
WO1995022600A1 (en) * | 1994-02-22 | 1995-08-24 | Immusol, Inc. | Ribozyme therapy for hepatitis b infection |
-
1996
- 1996-08-29 WO PCT/US1996/013975 patent/WO1997008309A2/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6043077A (en) | Hepatitis C virus ribozymes | |
Birikh et al. | The structure, function and application of the hammerhead ribozyme | |
Welch et al. | Intracellular application of hairpin ribozyme genes against hepatitis B virus | |
AU702373B2 (en) | Stabilized external guide sequences | |
Heidenreich et al. | Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. | |
Lieber et al. | Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library | |
JP4330797B2 (en) | Ribozyme capable of inhibiting expression of CCR5 receptor | |
US5567604A (en) | Anti-viral guanosine-rich oligonucleotides | |
US6057153A (en) | Stabilized external guide sequences | |
US6107028A (en) | Ribozymes for treating hepatitis C | |
Amarzguioui et al. | Hammerhead ribozyme design and application | |
EP0784094B1 (en) | Ribozyme -snRNA chimeric molecules having a catalytic activity for nuclear RNAs | |
WO2005040388A2 (en) | Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments | |
WO2000032765A9 (en) | Ribozyme therapy for the treatment and/or prevention of restenosis | |
US20080317717A1 (en) | Anti-hepatitis b virus ribozymal nucleic acid | |
WO1997010334A2 (en) | Ribozyme therapy for the treatment and/or prevention of restenosis | |
JP2003511025A (en) | Modification of gene expression by ssDNA produced in vivo | |
WO1997008309A9 (en) | Ribozyme therapy for hepatitis b infections | |
WO1997008309A2 (en) | Ribozyme therapy for hepatitis b infections | |
US6656731B1 (en) | Nucleic acid catalysts with endonuclease activity | |
Rossi | Therapeutic ribozymes: principles and applications | |
Elkins et al. | Cellular delivery of ribozymes | |
WO1995022600A1 (en) | Ribozyme therapy for hepatitis b infection | |
WO1999055856A2 (en) | Nucleic acid enzyme for rna cleavage | |
IL142492A (en) | GENETIC CONSTRUCTS FOR PRODUCING REGULATORY ssDNA TRANSCRIPTS INSIDE A CELL, COMPOSITIONS AND METHOD OF USE |